Clinical Trial Update: Phosphodiesterase-5 (PDE5) Inhibition and Pulmonary Hypertension in Diastolic Heart Failure [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 clinical trials investigating phosphodiesterase-5 inhibition for pulmonary hypertension in diastolic heart failure have been completed, sponsored by t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction
• Pulmonary Hypertension

Snippet

Sponsor: University of Milan | Conditions: Pulmonary Hypertension, Diastolic Heart Failure | Phase 2, Phase 3 | Status: COMPLETED